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Atrial fibrillation (AF) is the most common sustained arrhythmia, and patients with diabetes 
mellitus (DM) present an increased incidence of AF. Besides DM, heart failure shares 
pathophysiological links with AF, mainly related to the pathological remodeling of hearts affected 
by structural disease. As in a vicious circle, AF may contribute to heart failure worsening and 
increased mortality in patients with structural heart diseases, and the outcome may be further 
impaired when concomitant DM is present. Although no data directly referring to DM patients with 
heart failure are available, indirect information can be drawn from large studies on patients with HF 
and AF. The present review discusses the outcome of AF ablation in patients with DM and HF, 
focusing on safety, efficacy and most of all hard endpoints such as mortality and thromboembolic 
events incidence. 
 






Atrial fibrillation (AF) is the most common sustained arrhythmia, and patients with diabetes 
mellitus (DM) present an increased incidence of AF [1,2,3]. DM impacts coronary micro- and 
macrovasculature resulting in left ventricular systolic and diastolic dysfunction, leading to increased 
incidence of heart failure (HF) and, consequently, atrial structural remodeling [4,5]. Patients with 
DM present high levels of inflammatory markers [6,7], and chronic inflammation results in 
accelerated myocyte breakdown and fibrosis [8,9]. Finally, diabetic autonomic neuropathy can 
increase the risk of AF occurrence [10,11] through the imbalance of the autonomic nervous system, 
and potentially raises the risk of thromboembolic events [12]. Besides DM, HF shares 
pathophysiological links with AF, as this arrhythmia is relatively common in patients with HF [13]. 
Conversely, AF occurrence frequently contributes to HF worsening and increased mortality in 
patients with structural heart diseases, resulting in a vicious circle of whom the optimal treatment is 
difficult to identify [14,15]. 
Catheter ablation is an established treatment option for symptomatic AF [16]. Recent evidences 
suggest that this procedure is safe and effective even in patients with HF and DM [17,18], providing 
also long-term survival benefits in HF patients [19]. However, no studies have been performed to 
specifically address diabetic patients with HF. 
The present review aims to discuss the outcome of AF ablation in patients with DM and HF, 
focusing on safety, efficacy and most hard endpoints such as mortality. 
 
  
Pathophysiological links between AF, HF and DM 
Multiple mechanisms link AF and HF, as disadvantageous remodeling mechanisms occur as 
compensation in failing hearts [20,21,22]. Electrical, mechanical and metabolic alterations attempt 
to preserve an adequate cardiac output, resulting in elevation of left ventricular and atrial pressure, 
dilation, fibrosis, functional mitral regurgitation and autonomic imbalance, favouring AF 
occurrence and perpetuation.  
Conversely, AF can further impair left ventricular function in patients with structural heart disease, 
due to the fast and irregular rates and the loss in left atrial contraction, resulting in a tachycardia-
induced cardiomyopathy and further acceleration of the HF natural history [23,24].  
DM patients, instead, present a complex electrical and anatomical atrial substrate, due to the 
frequent coexistence of comorbid cardiovascular disease, resulting in atrial myocytes alterations 
[6,25] and potentially higher AF occurrence and recurrences despite rhythm control therapies. 
Additionally, a sort of “diabetic cardiomyopathy” has been proposed as an entity sharing common 
features with other structural cardiomyopathies resulting in HF, confirming the important role 
played by DM [26,27] (Figure 1). 
 
AF ablation in patients with HF 
During the last years several studies have been performed to assess the outcome of AF ablation in 
HF [28,29,30,31,32]. The safety and efficacy of the procedure were similar to that reported among 
the general population, and an improvement in NYHA class and left ventricular function were 
consistently found. A large meta-analysis reported a reduction in the proportion of patients 
presenting an ejection fraction lower than 35% [17]. Additionally, these benefits were maintained 
over follow-up, being higher in patients maintaining sinus rhythm and in those with a shorter 
history of AF and HF duration [33].  
Concerning quality of life, AF ablation reduced the number and duration of hospitalizations from 
HF compared to patients not treated by ablation [34]. Another meta-analysis including 17 
randomized trials of patients both with and without HF, showed significant benefit in terms of all-
cause mortality and hospitalizations for worsening HF in patients with AF and HF treated by 
catheter ablation compared to those treated by medical therapy [35]. 
A randomized trial comparing catheter ablation to amiodarone for AF treatment in patients with HF, 
the AATAC-AF trial, showed a significantly higher efficacy and lower complications for AF 
ablation [36]; finally, the CASTLE-AF trial [19], reported a significant benefit for AF ablation in 
terms of hard endpoints such as mortality, stroke incidence and hospitalization for worsening HF 
compared to medical therapy in patients with AF and HF.  
 
How to treat AF in diabetic patients? 
Previous studies showed that DM patients with AF are affected by a worse prognosis than those in 
sinus rhythm, both concerning quality of life, hospitalizations and mortality [37,38].  Therefore, 
rhythm control strategies may reduce or negate the long-term effect of AF in DM patients, turning 
into prognostic positive effects. However, despite limited to small non-randomized studies, higher 
recurrences after AF cardioversion [39], and lower in vitro and in vivo efficacy of anti-arrhythmic 
drugs [40,41] have been described in patients with compared to those without DM.  
The largest evidence on AF ablation outcome in patients with DM derives from a multicenter meta-
analysis, showing that AF ablation is safe, and long-term efficacy rates were favourable, as 
approximately half of the patients were free from AF following the first procedure, improving to 
65% including repeated procedures [18]. Advanced age and higher basal glycated haemoglobin 
levels have been identified as predictors of AF recurrences: optimal glycaemic control may, 
therefore, contribute to optimize AF treatment [18,42,43].  
However, higher readmission rates have been described for patients with compared to those without 
DM following AF catheter ablation [44], along with higher incidence of follow-up adverse events 
[45], even among those with insulin resistance [46]. Additionally, patients with poor glycaemic 
control or long-term DM history more frequently required aggressive LA substrate modification 
instead of pulmonary vein isolation alone [47], as already reported for HF patients [48]. These 
reports support the presence of a peculiar LA substrate in DM patients suffering from AF, 
warranting careful attention in defining the optimal treatment in this high-risk subset population. 
Current evidence on outcome of AF ablation in patients with DM, with or without concomitant HF, 
is summarized in Table 1. 
 
Diabetic patients with AF and HF 
Although no data directly referring to diabetic patients with HF are available, some indirect 
information can be drawn from large studies on AF ablation (Figure 1).  
The CASTLE-AF trial [19] enrolled overall 110 diabetic patients, 30% of the entire population, 43 
of whom in the ablation group. The primary endpoint (composite of death and hospitalization for 
HF) occurred in 19 (44%) patients in the ablation group and in 34 (50%) patients in the medical 
group, with a slightly higher incidence compared to the unselected study population (28.5% and 
44.6% in the ablation and medical therapy group, respectively). Despite the difference between 
diabetic and non-DM patients was non-significant, HR for death or hospitalization for HF was 1.01 
in the first, compared to 0.55 in the latter groups, suggesting a trend towards a minor AF ablation 
effect within DM patients. In any case, despite the trial was not designed and powered to investigate 
the outcome in subset populations, and DM patients are a limited amount of the overall population, 
these data suggest that HF patients with concomitant DM represent a very high-risk population. 
Conversely, in the meta-analysis from our group [17] only 12(9-15)% patients were affected by 
DM; this comorbidity did not relate to incidence of arrhythmic recurrences compared to non-
diabetics; however, the limited number of patients and the meta-analytic nature of this data limit the 
strength of the finding. 
Finally, the AATAC-AF trial [36] included 22% and 24% patients affected by DM in the ablation 
and amiodarone groups, respectively. Of note, DM was one of the predictors of AF recurrences (HR 
2.22 at univariate, 1.10 at multivariate analysis, p=0.010). Moreover, DM was the only significant 
clinical predictor of AF recurrences, along with amiodarone treatment, suggesting the lower 
efficacy of AF ablation in this subset population. No data however have been provided on mortality 
in diabetic patients.  
   
Conclusion 
Patients with HF and DM represent a high-risk population, in whom AF occurrence may result in 
even worse outcome despite the most effective treatments. AF ablation in this subset population, in 
fact, may be affected by a lower efficacy and higher incidence of long-term follow-up 
complications, resulting in a limited impact on long-term survival. Future studies are warranted to 
identify the impact of AF ablation on hard endpoints, such as mortality and stroke, in this high-risk 
population of diabetic patients with HF. 
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Table 1. First Author, publication date, population and main characteristics of the studies reporting 
on AF ablation outcome in diabetic patients. 
First Author, 
Country, Year of 
Publication 














1464 27 65 62 66 
Lu, China, 2015 
[43] 
Retrospective
, single center 










64 12 100 45 83 












43 38 30 64 N/A – higher 
mortality/HF 
 
AF: atrial fibrillation. DM: diabetes mellitus. HF: heart failure.  
  
Figure 1. Diabetes mellitus, heart failure and atrial fibrillation. The pathophysiological interaction 
is presented in the left panel, and the impact of diabetes on atrial fibrillation ablation outcome is 
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